BR112020011055A2 - tetratiomolibdato de bis-colina para tratar doença de wilson - Google Patents

tetratiomolibdato de bis-colina para tratar doença de wilson Download PDF

Info

Publication number
BR112020011055A2
BR112020011055A2 BR112020011055-8A BR112020011055A BR112020011055A2 BR 112020011055 A2 BR112020011055 A2 BR 112020011055A2 BR 112020011055 A BR112020011055 A BR 112020011055A BR 112020011055 A2 BR112020011055 A2 BR 112020011055A2
Authority
BR
Brazil
Prior art keywords
bis
patient
choline tetrathiomolybdate
dose
day
Prior art date
Application number
BR112020011055-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Carl Bjartmar
Karl-Heinz Weiss
Michael Schilsky
Frederick Askari
Anna Czlonkowska
Peter Ferenci
Peter Hedera
Aftab Ala
Original Assignee
Alexion Pharma International Operations Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma International Operations Unlimited Company filed Critical Alexion Pharma International Operations Unlimited Company
Publication of BR112020011055A2 publication Critical patent/BR112020011055A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112020011055-8A 2017-12-04 2018-12-04 tetratiomolibdato de bis-colina para tratar doença de wilson BR112020011055A2 (pt)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US62/594,184 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US62/646,553 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US62/655,568 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US62/669,095 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US62/741,313 2018-10-04
US201862750595P 2018-10-25 2018-10-25
US62/750,595 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Publications (1)

Publication Number Publication Date
BR112020011055A2 true BR112020011055A2 (pt) 2020-11-17

Family

ID=64661349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020011055-8A BR112020011055A2 (pt) 2017-12-04 2018-12-04 tetratiomolibdato de bis-colina para tratar doença de wilson

Country Status (16)

Country Link
US (3) US11510944B2 (https=)
EP (3) EP4523745A3 (https=)
JP (3) JP7852200B2 (https=)
KR (1) KR102803161B1 (https=)
AU (1) AU2018379255B2 (https=)
BR (1) BR112020011055A2 (https=)
DK (2) DK4029498T3 (https=)
ES (2) ES3026756T3 (https=)
FI (1) FI4029498T3 (https=)
HU (2) HUE071155T2 (https=)
IL (1) IL275115B2 (https=)
MX (1) MX2020006284A (https=)
PL (2) PL4029498T3 (https=)
PT (2) PT4029498T (https=)
SI (2) SI4029498T1 (https=)
WO (1) WO2019110619A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) * 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate
US20220387370A1 (en) 2019-11-21 2022-12-08 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
CN116601173A (zh) * 2020-09-11 2023-08-15 阿雷克森制药公司 抗铜蓝蛋白抗体及其用途
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
JP2024505229A (ja) * 2021-01-31 2024-02-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療するための新規製剤
WO2023023199A1 (en) 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2024162974A1 (en) 2023-01-30 2024-08-08 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
GEP20074270B (en) * 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
CA2675230A1 (en) 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate

Also Published As

Publication number Publication date
EP4029498B1 (en) 2025-02-05
ES2912306T3 (es) 2022-05-25
EP3720433A1 (en) 2020-10-14
IL275115B1 (en) 2025-06-01
EP4523745A3 (en) 2025-05-14
DK3720433T3 (da) 2022-05-02
HUE058921T2 (hu) 2022-09-28
JP2021505655A (ja) 2021-02-18
IL275115A (en) 2020-07-30
PT4029498T (pt) 2025-05-06
RU2020122023A (ru) 2022-01-10
AU2018379255B2 (en) 2024-10-17
HUE071155T2 (hu) 2025-08-28
PT3720433T (pt) 2022-05-03
JP7852200B2 (ja) 2026-04-28
US20210137972A1 (en) 2021-05-13
KR102803161B1 (ko) 2025-05-07
MX2020006284A (es) 2021-04-12
US20230070534A1 (en) 2023-03-09
DK4029498T3 (da) 2025-04-28
EP4523745A2 (en) 2025-03-19
FI4029498T3 (fi) 2025-04-29
US20210177894A1 (en) 2021-06-17
PL3720433T3 (pl) 2022-07-18
WO2019110619A1 (en) 2019-06-13
KR20200096798A (ko) 2020-08-13
AU2018379255A1 (en) 2020-06-25
ES3026756T3 (en) 2025-06-12
JP2025066802A (ja) 2025-04-23
EP4029498A1 (en) 2022-07-20
IL275115B2 (en) 2025-10-01
SI3720433T1 (sl) 2022-09-30
US11510944B2 (en) 2022-11-29
EP3720433B1 (en) 2022-02-02
US12233088B2 (en) 2025-02-25
CA3084100A1 (en) 2019-06-13
SI4029498T1 (sl) 2025-07-31
PL4029498T3 (pl) 2025-06-02
JP2023075247A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
US12233088B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
US20220152055A1 (en) Methods and compositions for treating various disorders
CN103974619B (zh) 治疗法布里病的给药方案
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
CA3084100C (en) Bis-choline tetrathiomolybdate for treating wilson disease
CA3230084A1 (en) Methods of treating copper metabolism-associated diseases or disorders
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
CN121358471A (zh) 用于治疗铜代谢相关疾病或病症(威尔逊病)的四硫代钼酸
HK40081935A (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022024843-8 PROTOCOLO 870220113197 EM 05/12/2022 15:42.

B25D Requested change of name of applicant approved

Owner name: ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]